Eton Pharmaceuticals has acquired Galzin (zinc acetate), a US Food and Drug Administration (FDA)-approved maintenance treatment for Wilson Disease, from Teva Pharmaceuticals USA.
Galzin is indicated for those who have been initially treated with a chelating agent.
As part of the acquisition agreement, Eton Pharmaceuticals secured ownership of Galzin with an upfront payment of $7m, supplemented by an additional $0.2m to cover inventory costs.
Beyond the initial payments, Eton Pharmaceuticals committed to paying Teva Pharmaceuticals a 10% royalty on net sales of the product in the US. This royalty arrangement will remain in effect for ten years, starting from the date of Galzin’s first commercial sale in the US.
Eton Pharmaceuticals plans to commercialise Galzin in the US by Q1 2025. The product will be supported by its metabolic sales team, assisting healthcare professionals treating Wilson Disease.
Through the Eton Cares programme, the company will offer $0 co-pays for eligible patients, prescription fulfilment, insurance support, and educational resources to ensure access to treatment.
Eton Pharmaceuticals has also acquired European rights to Galzin, marketed as Wilzin by a third party.
The rare disease drugmaker will continue supplying the product to the third party, which is responsible for commercialisation in Europe.
Eton Pharmaceuticals CEO Sean Brynjelsen said: “This acquisition furthers our mission of supporting life-saving treatments for conditions impacting ultra rare patient populations.
“Galzin is a critical medication for patients with Wilson Disease, and we look forward to supporting these patients with our comprehensive Eton Cares patient support programme.”
Stifel acted as Eton Pharmaceuticals’ exclusive financial adviser for the transaction.
Eton Pharmaceuticals has six commercial products, which are INCRELEX, ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone.
The pharma company also has four late-stage product candidates, ET-400, ET-600, Amglidia, and ZENEO hydrocortisone autoinjector.
In December last year, the drugmaker completed its previously announced asset purchase of Increlex (mecasermin injection) from Ipsen.
INCRELEX is indicated for paediatric patients aged two and older with severe primary insulin-like growth factor 1 deficiency (SPIGFD).
In November 2024, Eton Pharmaceuticals acquired the US rights to Amglidia (glyburide oral suspension) from French pharma firm AMMTeK.
